Killer acquisitions

Fierce debate now surrounds whether antitrust enforcers are doing enough to protect budding innovators. During GCR Live’s second annual pharmaceuticals conference in February, a panel of antitrust lawyers who regularly advise drug makers warned against a heavy-handed merger enforcement approach that could stymie life-saving innovation.

Get unlimited access to all Global Competition Review content